Eli Lilly's $3B Wisconsin Expansion to Boost Obesity Drug Production
TL;DR Summary
Eli Lilly and Company announced a $3 billion expansion of its Pleasant Prairie facility, expected to create 750 jobs and boost production of its popular weight loss medications, Mounjaro and Zepbound. The expansion aims to address supply chain issues and meet rising demand for these injectable drugs, which help with weight loss and diabetes management. Construction is set to begin next year, following the facility's acquisition from Nexus Pharmaceuticals earlier this year.
- Eli Lilly announce $3 billion expansion at Pleasant Prairie facility WISN Milwaukee
- Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars CNBC
- Drug maker Lilly announces $3 billion expansion, 750 new jobs in Kenosha County. Milwaukee Journal Sentinel
- Evers announces $3 million expansion of manufacturing facility in Wisconsin Channel3000.com - WISC-TV3
- Lilly continues to expand its empire of GLP-1 factories with new $3B buildout Endpoints News
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
87%
571 → 72 words
Want the full story? Read the original article
Read on WISN Milwaukee